Physician profile
Mackenzie Lynn Moore
NPI 1578380986
$1,252.56
in general payments reported to CMS, 2019-2025
12 companies · $1,253 in 2025
The $1,253 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,252.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $325.12 | 2025 | Camzyos, Eliquis |
| Inspire Medical Systems, INC. | $205.53 | 2025 | Inspire |
| Alnylam Pharmaceuticals INC. | $176.26 | 2025 | Amvuttra, Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $127.93 | 2025 | Lifevest |
| Merck Sharp & Dohme LLC | $117.69 | 2025 | Verquvo, Capvaxive |
| Pfizer INC. | $86.67 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $62.04 | 2025 | Farxiga, Lokelma |
| Novo Nordisk INC | $37.15 | 2025 | Wegovy |
| Abiomed | $36.78 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.14 | 2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $22.68 | 2025 | |
| Bridgebio Pharma, INC. | $20.57 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.